Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.
Jay Chhablani, MD
Advertisement
Articles by Jay Chhablani, MD
The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.
Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
How European clinicians are revolutionizing retina care
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
4
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
5
